{
    "clinical_study": {
        "@rank": "168153", 
        "arm_group": [
            {
                "arm_group_label": "Cohort 1", 
                "arm_group_type": "Experimental", 
                "description": "100mg HM61713 single dose in Korean"
            }, 
            {
                "arm_group_label": "Cohort 2", 
                "arm_group_type": "Experimental", 
                "description": "200mg HM61713 single dose in Korean"
            }, 
            {
                "arm_group_label": "Cohort 3", 
                "arm_group_type": "Experimental", 
                "description": "300mg HM61713 single dose in Korean"
            }, 
            {
                "arm_group_label": "Cohort 4", 
                "arm_group_type": "Experimental", 
                "description": "200mg HM61713 single dose in Japanese"
            }, 
            {
                "arm_group_label": "Cohort 5", 
                "arm_group_type": "Experimental", 
                "description": "300mg HM61713 single dose in Japanese"
            }, 
            {
                "arm_group_label": "Cohort 6", 
                "arm_group_type": "Experimental", 
                "description": "200mg HM61713 single dose in Caucasian"
            }, 
            {
                "arm_group_label": "Cohort 7", 
                "arm_group_type": "Experimental", 
                "description": "300mg HM61713 single dose in Caucasian"
            }
        ], 
        "brief_summary": {
            "textblock": "Study Design\n\n        -  Open, escalating single-dose design.\n\n        -  7 ascending dose cohorts\n\n        -  In each cohorts, subjects will receive a single dose of HM61713.\n\n        -  Main objective of this study is to evaluate the pharmacokinetics of HM61713 tablet."
        }, 
        "brief_title": "Study to Evaluate a Pharmacokinetic of HM61713 in Healthy Male Subjects", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "Secondary objectives\n\n        -  to evaluate the safety and tolereability of HM61713 tablet in healthy male subjects.\n\n        -  to evaluate food effect on PK characteristics of HM61713 tablet in healthy male\n           subjects."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male volunteers, age between 20 and 45\n\n          -  Informed of the investigational nature of this study and voluntarily agree to\n             participate in this study\n\n          -  BMI of \uff1e18.5kg/m2 and \uff1c28kg/m2 subject\n\n        Exclusion Criteria:\n\n          -  Use of any prescription medication within 2 weeks prior to Day 1\n\n          -  Use of any medication within 1 weeks prior to Day 1\n\n          -  Has a severe medical history of hypersensitivity to drug\n\n          -  Participation in another clinical study within 8 weeks days prior to start of study\n             drug administration"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "56", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01894399", 
            "org_study_id": "HM-EMSI-102"
        }, 
        "intervention": {
            "arm_group_label": [
                "Cohort 1", 
                "Cohort 2", 
                "Cohort 3", 
                "Cohort 4", 
                "Cohort 5", 
                "Cohort 6", 
                "Cohort 7"
            ], 
            "intervention_name": "HM61713 tablet", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "HM61713", 
        "lastchanged_date": "July 3, 2013", 
        "location": {
            "contact": {
                "last_name": "In-Jin Jang, MD, PhD"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Seoul National University Hospital"
            }, 
            "investigator": {
                "last_name": "In-Jin Jang, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "7", 
        "official_title": "Phase \u2160 Study to Assess the Safety, Tolerability, Pharmacokinetic Characteristics of HM61713 Tablet in Healthy Korean, Japanese and Caucasian", 
        "overall_contact": {
            "email": "kmpark@hanmi.co.kr", 
            "last_name": "Kyung-Mi Park, PhD"
        }, 
        "overall_official": {
            "affiliation": "Seoul National University Hospital", 
            "last_name": "In-Jin Jang, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Cmax, AUC, Tmax, T1/2, fe, CL/F, CLR, Vd, MRT of HM61713 and Metaboletes(M1, M2)", 
            "measure": "Plasma/Urine PK parameters", 
            "safety_issue": "No", 
            "time_frame": "0-48 hrs"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01894399"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Safety data, including physical examinations, laboratory evaluation, ECGs, ICGs, vital signs, and adverse events.", 
            "safety_issue": "Yes", 
            "time_frame": "7 days after the investigational drug administration."
        }, 
        "source": "Hanmi Pharmaceutical Company Limited", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hanmi Pharmaceutical Company Limited", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}